Actelion Stops Tezosentan Trial
This article was originally published in The Pink Sheet Daily
The acute heart failure drug has "too remote a chance" of reaching statistically significant efficacy endpoints, an interim analysis by the data safety monitoring board finds. Actelion will wait for a complete analysis of the data before making a further developmental decisions for tezosentan, which would be co-promoted by Genentech.
You may also be interested in...
Swiss firm blames currency fluctuations and buying patterns for Tracleer and Ventavis sales reductions.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.